What this trial studies
Gum Arabic ingestion has been proved to decrease some of the inflammatory markers in some metabolic diseases that have an inflammatory background. Nevertheless, the mechanism/s by which it does so is uncertain. This study is targeting one of the postulated molecular mechanisms at genetic level that may help to understand how Gum Arabic exerts its effect .The effects of GA on Nuclear Factor Kappa Beta, P38 Mitogen Activated Protein (MAP) Kinase levels, and on the expression of inflammatory cytokines genes are going to be assessed in postmenopausal females with Metabolic Syndrome.
Conditions in scope
- Metabolic Syndrome in Postmenopausal Females
Interventions
- Gum Arabic (Drug) — A dietary supplement (Powdered exudates of Acacia Senegal (Gum Arabic E-414))
Who can join
Women only · Ages 45 Years to 70 Years
Inclusion criteria
- See ClinicalTrials.gov for full inclusion criteria.
Exclusion criteria
- Patients with mental or physical disability
- Use of corticosteroids or any other drug that affects body weight
- History of Gum Arabic (GA) allergy
- Chronicrenal or liver disease
- Chronocinflammatory diseases
- History of CVA or MI Participants will be asked to maintain their habitually daily diet and level of activity during the period of the study and to continue any previously prescribed medication.
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Khartoum | University of Khartoum | Unknown |
Status & timeline
- Overall status: Completed
- Study type: Interventional
- Phase: PHASE2
- Start date: 2019-12-04
- Primary completion: 2021-01-10
- Last update posted: 2026-02-18
- First posted: 2021-07-27
Sponsor & contact
Lead sponsor: University of Khartoum (Other)
Collaborators: Ministry of Higher Education and Scientific Research, Republic of Sudan
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Nuclear Factor Kappa Beta concentration in nanogram/dl (12 weeks)
Nuclear regulatory protein - P38 Mitogen activated protein kinase in nanogram/dl (12 weeks)
Transcription regulatory protein - Inhibitory Kappa Beta protein in nanogram/dl (12 weeks)
inhibitory protein - Tumor necrosis factor, interferon gamma and interleukin-6 in nanogram/dl (12 weeks)
Proinflammatory cytokines - Plasminogen activated protein inhibitor1 in picogram/dl (12 weeks)
Protein Inhibitor
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT04978103 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.